Compare Novo Nordisk A/S (NVO) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Novo Nordisk A/S trades at $45.04 (market cap $198.57B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.19. The key difference: Novo Nordisk A/S pays a 4.03% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NVO | YMAG | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $15.98 |
52-Week Low | $35.29 | $10.76 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
YMAG trades at $11.26, down 0.18% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation metrics remain unavailable. Recent trading activity shows moderate volume with price stability around the $11 support level.
The outlook remains cautiously optimistic given the bullish technical setup and income generation, but lack of fundamental data creates uncertainty. Investors face risks from NAV volatility during earnings periods and dependency on option income strategies for distributions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
